Santen to Present Glaucoma/OcularHypertension Data at AAO 2020 Virtual
Santen announced that the following talks on glaucoma and ocular hypertension will be presented at the American Academy of Ophthalmology (AAO) Virtual 2020 meeting.
Poster Topic: MicroShunt (or DE-128), an investigational surgical glaucoma implant designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications. Poster Presentation Discussion on Glaucoma: Saturday, Nov. 14, 1:00 p.m. PST
- Poster PO189: One-Year Safety and Effectiveness of Microshunt vs. Trabeculectomy in Sites in the USA and Europe in a Randomized Study
- Poster PO193: Safety Outcomes of Microshunt Implantation vs. Trabeculectomy in Patients With POAG
Poster Topic: Omidenepag isopropyl ophthalmic solution 0.002% (or DE-117), an investigational topical ophthalmic solution for the treatment of elevated IOP in patients with glaucoma or ocular hypertension.
- Poster PO178:Randomized Phase 2 Trial Assessing the Safety and Efficacy of Omidenepag Isopropyl 0.002% Once and Twice Daily
- Poster PA020:Safety and Efficacy of Omidenepag Isopropyl, an EP2 Agonist, in Multicenter Observational Study in Japan: Interim Results
Industry-Sponsored Presentations: Additionally, Santen is participating in several industry-sponsored presentations:
- Characterizing Vernal Keratoconjunctivitis Epidemiology and Treatment Patterns in the United States – Friday, Nov. 13, 5:30 a.m. PST
- Subconjunctival Glaucoma Surgery and MicroShunt – Friday, Nov. 13, 1:35 p.m. PST
- Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C – Saturday, Nov. 14, 10:35 a.m. PST
- Vernal Keratoconjunctivitis – A Disease Awareness Conversation – Saturday, Nov. 14, 9:40 a.m. PST and Sunday, Nov. 15, 8:35 a.m. PST
- One-year Safety and Effectiveness of MicroShunt Implantation versus Trabeculectomy across Five European Sites – Sunday, Nov. 15, 1:00 p.m. PST